An important advancement in the management of EB was the approval of the topical gene therapy beremagene geperpavec (Vyjuvek®), indicated for patients with dystrophic EB caused by COL7A1 mutations [62]. This evidence concerns the gene COL7A1 and epidermolysis bullosa.